ClinicalTrials.gg
CompletedNCT06368986Updated Feb 18, 2025

A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

A Phase 1 interventional study of VH4011499 Dose A and VH4011499 Dose B in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-18.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 266 studies in HIV Infections by GlaxoSmithKline — 15 open to participants now, 27 under way, 8 of them phase 3. HIV Infections · GlaxoSmithKline.

Enrollment
116th of 210
60 · median 82
Started
2024
with 10 others
Phase 1
83 of 266
9 open now
Registered
247th of 266
by date

Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 116th largest by enrollment of the 210 interventional ones that give a count, is one of 11 that started in 2024, is one of 83 in phase 1, and was the 247th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

15 of the 266 studies in HIV Infections by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in HIV Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate effect of food (in fasted and fed conditions) on the bioavailability of CAI VH4011499.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Fasted condition
  • Fed condition
  • Bioavailability
  • Capsid inhibitor
  • VH4011499
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are 18 to 55 years of age.
  • Participants who are overtly healthy.
  • One SARs-CoV-2 negative test is required prior to dosing
  • Body weight within 50-100 kg and (BMI) within the range 19-32 kg/m2 (inclusive).
  • Capable of giving signed .
  • Participants male at birth must use male condoms, and participants female at birth who are of must be using acceptable forms of .

Exclusion criteria

Exclusion Criteria:

  • History or presence of disorders capable of significantly altering the absorption, metabolism, or elimination of drugs.
  • Current or chronic liver disease, hepatic or biliary abnormalities, or relevant hepatitis.
  • Abnormal blood pressure.
  • Any within the past 5 years except certain localized malignancies, or breast cancer within the past 10 years. Participants with exclusionary findings.Positive test or ongoing behaviors that put the participant at high risk for HIV acquisition.
  • Participants who are breastfeeding or plan to become pregnant during the study.
  • Past or intended use of exclusionary medications or vaccines.
  • Exposure to >4 new products within 12 months, previous participation in this study, or current enrolment or participation in another investigational study.
  • >1.5x (ULN), total >1.5x ULN, and/or estimated serum \<60 mL/min.
  • History of or current infection with or .
  • Positive SARS-CoV-2 test, having signs and symptoms suggestive of COVID-19, or contact with known COVID-19 positive person.
  • Positive HIV antibody test.
  • Participants with positive results for illicit drug use, regular use of drugs of abuse, tobacco or nicotine-containing product use, and/or excessive alcohol use.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Part 1 Dose A - Fasted condition

    VH4011499 Dose A tablet administered in fasted condition.

    Drug: VH4011499 Dose A

  • Experimental
    Part 1 Dose A- Fed condition (high fat meal)

    VH4011499 Dose A tablet administered in fed condition (high fat meal).

    Drug: VH4011499 Dose A

  • Experimental
    Part 2 Dose B - Optional - Fed condition (low fat meal)

    VH4011499 Dose B tablet administered in fed condition (low fat meal).

    Drug: VH4011499 Dose B

  • Experimental
    Part 3 Dose B - Fasted condition

    VH4011499 Dose B tablet administered in fasted condition.

    Drug: VH4011499 Dose B

  • Experimental
    Part 3 Dose B - Fed condition (high fat meal)

    VH4011499 Dose B tablet administered in fed condition (high fat meal).

    Drug: VH4011499 Dose B

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration - time curve from time zero (pre-dose) to infinity time (AUC[0-inf]) of VH4011499

    Time frame: From Day 1 (pre-dose) to Day 28

  2. Area under the plasma drug concentration - time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-tlast) of VH4011499

    Time frame: From Day 1 (pre-dose) to Day 28

  3. Maximum observed plasma drug concentration (Cmax) of VH4011499

    Time frame: From Day 1 (pre-dose) to Day 28

  4. Time to maximum observed plasma concentration (Tmax) of VH4011499

    Time frame: From Day 1 (pre-dose) to Day 28

Secondary outcomes

  1. Number of participants with AEs (Adverse Events), by severity

    An AE is any untoward medical occurrence in a participant or clinical investigation participant and can be any sign, symptom, or disease temporally associated with the use of a medicinal product. The severity scale is assessed as following: Grade 1 = mild symptoms causing no or minimal interference with usual social and functional activities with intervention not indicated. Grade 2 = moderate symptoms causing greater than minimal interference with usual social and functional activities with intervention indicated. Grade 3 = severe symptoms causing inability to perform usual social and functional activities with intervention or hospitalization indicated. Grade 4 = potentially life-threatening symptoms causing inability to perform self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death, Grade 5 = death.

    Time frame: From Day 1 (pre-dose) to Day 28

  2. Number of participants with maximum toxicity grade increase from baseline for liver laboratory parameters

    The assessed laboratory assessments include Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), alkaline phosphatase (ALP), direct bilirubin and total bilirubin, in both fed and fasted conditions.

    Time frame: From Day 1 (pre-dose) to Day 28

  3. Change from baseline in liver panel parameters: total bilirubin and direct bilirubin (micromoles per liter)

    Time frame: From Day 1 (pre-dose) to Day 28

  4. Change from baseline in liver panel parameters: ALT, ALP and AST (International units per liter)

    Time frame: From Day 1 (pre-dose) to Day 28

07

Study locations

1 site
  • GSK Investigational Site
    Austin, Texas 78744 -1645, United States
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_25Sep2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.viiv-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Oct 2024, 5 months.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 5 months is close to that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2024
First posted
Apr 16, 2024
StartActual
Apr 17, 2024
Primary completionActual
Oct 2, 2024
CompletionActual
Oct 2, 2024
Last update
Feb 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06368986
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
Apr 17, 2024
Primary completion
Oct 2, 2024
Completion
Oct 2, 2024
Last update
Feb 18, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dezecapavir

Start the discussion